Cummings James F. 4

4 · Vaxart, Inc. · Filed Mar 18, 2026

AI-generated summary of this filing

Updated Mar 18, 2026

Vaxart (VXRT) CMO James F. Cummings Receives Award

What Happened

James F. Cummings, Chief Medical Officer of Vaxart, received two equity awards on March 16, 2026: 227,000 shares delivered as restricted stock units (RSUs) and a 455,000-share derivative award (stock option). Both items are reported with a $0.00 acquisition price, meaning these are company awards/grants rather than open-market purchases or sales. No cash was paid by the insider in these reported transactions.

Key Details

Transaction date: March 16, 2026; Form 4 filed March 18, 2026 (timely filing — within the standard 2 business days).
Reported amounts and prices: 227,000 RSUs @ $0.00; 455,000 derivative shares (option grant) @ $0.00.
Shares owned after transaction: Not specified in the filing.
Footnotes / vesting:
- F1 (RSUs): 25% of the RSUs vest on each anniversary of the vesting commencement date (March 16, 2026), so the RSUs fully vest on the fourth anniversary.
- F2 (option): 25% of the option vests March 16, 2027, then vests in 36 equal monthly installments thereafter, with full vesting on March 16, 2030.
No indication of immediate sale (not a cashless exercise) or a 10b5-1 plan; these are standard compensation awards.

Context

These entries are awards/compensation grants (neutral in the short term) rather than insider purchases (which some investors view as a bullish signal) or sales (which can be liquidity-driven). For the derivative option grant, vesting schedules mean the shares/options will not be fully usable by the insider until the stated vesting dates.

Form 4

Period: 2026-03-16

Chief Medical Officer

Transactions

Award
Common Stock
[F1]
2026-03-16+227,000→ 964,792 total
Award
Stock Option (right to buy)
[F2]
2026-03-16+455,000→ 455,000 total
Exercise: $0.68Exp: 2036-03-16→ Common Stock (455,000 underlying)

Footnotes (2)

[F1]Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date.
[F2]The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030.

Signature

/s/ Edward Berg, Attorney-in-Fact|2026-03-18

1 file